Alnylam Pharmaceuticals, Inc. (ALNY) at Citi’s Biopharma Back to School Conference

David Lebowitz
Research Analyst

Thank you all. Welcome all again to the 2025 Citi Biopharma Conference in Boston. Next on the docket, we have Alnylam. If you could, I guess, introduce us and kind of tell us a little bit about the company for no one who’s — for people who haven’t heard of you before, bring us up to speed, that would be great.

Jeffrey Poulton
CFO & Executive VP

[indiscernible] very productive organic platform for the company. We’ve got 6 products in the market today, 4 of which that we’re marketing ourselves, which came out of our research labs, meaning the Skys Labs. And we’ve got a terrific pipeline of things that we think they are going to continue the growth trajectory for the company over the long term. And I know we’re going to get into a number of those topics here in the next 40 minutes. I think the big focus right now for investors on the company is clearly the launch in ATTR cardiomyopathy, and we reported strong initial results, which was in Q2 in terms of what we delivered. Again, I know we’re going to get into the details on that, but that enabled us to upgrade the guidance for this year pretty substantially, and I think got people pretty excited about what we were able to say about the initial demand for the product. So we’re excited. Yes.